Identifying the determinants of response to MDM2 inhibition
Metrics: PDF 1181 views | HTML 1389 views | ?
Anne Y. Saiki1, Sean Caenepeel1, Elissa Cosgrove2,5, Cheng Su3, Michael Boedigheimer4, Jonathan D. Oliner1
1Oncology Research, Amgen, Inc., Thousand Oaks, California, USA
2Genome Analysis Unit, Amgen, Inc., South San Francisco, California, USA
3Biostatistics, Amgen, Inc., Seattle, Washington, USA
4Molecular Sciences, Amgen, Inc., Thousand Oaks, California, USA
5Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York, USA
Jonathan D. Oliner, e-mail: email@example.com
Keywords: TP53, MDM2, amplification
Received: October 28, 2014 Accepted: January 08, 2015 Published: February 03, 2015
Previous reports have provided evidence that p53 mutation is a strong negative predictor of response to MDM2 inhibitors. However, this correlation is not absolute, as many p53Mutant cell lines have been reported to respond to MDM2 inhibition, while many p53WT cell lines have been shown not to respond. To better understand the nature of these exceptions, we screened a panel of 260 cell lines and noted similar discrepancies. However, upon extensive curation of this panel, these apparent exceptions could be eliminated, revealing a perfect correlation between p53 mutational status and MDM2 inhibitor responsiveness. It has been suggested that the MDM2-amplified subset of p53WT tumors might be particularly sensitive to MDM2 inhibition. To facilitate clinical testing of this hypothesis, we identified a rationally derived copy number cutoff for assignment of functionally relevant MDM2 amplification. Applying this cutoff resulted in a pan-cancer MDM2 amplification rate far lower than previously published.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.